In today’s blog Alan Kennedy, European Funding Advisor for the Research Support Office talks about the EU’s Innovative Medicines Initiative (IMI) upcoming call topics.
The Innovative Medicines Initiative (IMI) is a public-private partnership between the European Union and Pharmaceutical companies designed to improve the competitive situation of the European Union in the field of pharmaceutical research. In an effort to give potential applicants as much time as possible to form consortia and prepare their proposals, IMI has published draft text of the next proposed call topics. Below are links to documents outlining the specific challenge, scope, expected impact and other information.
It’s important to note that these draft topic texts are still to go through the IMI’s consultation and approval process, and so the final text may be different when the call is officially published. Some of the topics mentioned may not be included. However, this shouldn’t stop you thinking about the topic, whether it’s suitable for you and who you may like to work with. The date for their official publication is not yet known but we’ll keep you updated.
So far, the university has had significant success in these high-profile projects. We are part of three IMI projects awarded last week, bringing the total number of IMIs we’re involved in to 7, two of which we lead (EQIPD and RESCEU). Amazingly, we have an 87.5% success rate with IMI, which could be 100% as we’re awaiting the result of an 8th application, so fingers crossed!
IMI2, the current programme, has a budget of €3.3 billion. Details of previously funded projects can be found here. IMI are also focused on increasing the inclusion of SMEs, particularly in the areas of biotechnology, IT, or project management fields.
Draft text of the proposed topics:
- Targeted immune intervention for treatment of non-response and remission
- Non-invasive clinical molecular imaging of immune cells
- Development of a platform for federated and privacy-preserving machine learning in support of drug discovery
- Centre of excellence – remote decentralised clinical trials
If you’d like more information about IMI or to discuss the content of the draft calls please get in touch.
More from this author
